Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that the first patient has been dosed in the company’s Phase 2a RESET clinical trial evaluating JOTROL™ in patients with Parkinson’s disease (PD).

The dosing of the first patient represents an important clinical milestone for Jupiter and marks the transition of JOTROL™ into Phase 2a clinical evaluation in patients with Parkinson’s disease. The RESET study (NCT07592767) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and biomarker effects of JOTROL™, Jupiter’s investigational, proprietary micellar formulation of trans-resveratrol.